Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087179 | 0.87 | MET (0.74) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3064926 | 0.82 | MET (1.00) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3062559 | 0.81 | MET (0.66) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3047024 | 0.80 | MET (0.68) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3052484 | 0.80 | MET (0.68) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL13089761 | 0.80 | MET (0.79) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3052761 | 0.80 | MET (0.76) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3078895 | 0.80 | MET (0.77) | METMEN1KMT2A | |
| SCHEMBL3088627 | 0.80 | MET (1.00) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL13152176 | 0.80 | MET (0.77) | METMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221806-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | claimed |
| EP-2049531-B1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-09-24 | — | — | EP | claimed |
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2013-05-23 | — | — | US | claimed |
| US-8435981-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-05-07 | — | — | US | claimed |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-14 | — | — | US | claimed |
| US-9221806-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| EP-2049531-B1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8435981-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | RET, MET, ERBB2 | MET 2/4885MEN1 157/4885KMT2A 627/4885 |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885MEN1 166/4885KMT2A 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.